Published in Proc Natl Acad Sci U S A on January 14, 2013
Activation pathway of Src kinase reveals intermediate states as targets for drug design. Nat Commun (2014) 1.48
Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism. Science (2015) 1.30
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nat Struct Mol Biol (2014) 1.24
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet (2014) 1.03
P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. PLoS Comput Biol (2014) 0.95
Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. J Am Chem Soc (2013) 0.91
Measurement of small molecule binding kinetics on a protein microarray by plasmonic-based electrochemical impedance imaging. Anal Chem (2014) 0.85
Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity. J Am Chem Soc (2014) 0.84
Computational modeling of membrane proteins. Proteins (2014) 0.83
Calculating the sensitivity and robustness of binding free energy calculations to force field parameters. J Chem Theory Comput (2013) 0.83
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLoS Comput Biol (2015) 0.83
Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase. Sci Rep (2016) 0.81
Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. J Phys Chem B (2015) 0.81
Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS Chem Biol (2013) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem (2014) 0.78
Structural propensities of kinase family proteins from a Potts model of residue co-variation. Protein Sci (2016) 0.78
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway. Eur J Pharmacol (2015) 0.78
Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy. Sci Rep (2016) 0.77
Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations. J Am Chem Soc (2017) 0.77
Modeling molecular kinetics with tICA and the kernel trick. J Chem Theory Comput (2015) 0.76
Ensembler: Enabling High-Throughput Molecular Simulations at the Superfamily Scale. PLoS Comput Biol (2016) 0.75
The Endocytic Fate of the Transferrin Receptor Is Regulated by c-Abl Kinase. J Biol Chem (2016) 0.75
Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. PLoS One (2015) 0.75
Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3). J Comput Aided Mol Des (2015) 0.75
Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib. ACS Chem Biol (2016) 0.75
Dynamic Equilibrium of the Aurora-A Kinase Activation Loop Revealed by Single Molecule Spectroscopy. Angew Chem Int Ed Engl (2017) 0.75
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B (1998) 54.00
Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem (2004) 17.97
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13
Improved treatment of the protein backbone in empirical force fields. J Am Chem Soc (2004) 5.96
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Assessing protein structures with a non-local atomic interaction energy. J Mol Biol (1998) 4.42
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood (2007) 4.15
Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst (1960) 4.15
QMEAN: A comprehensive scoring function for model quality assessment. Proteins (2008) 3.90
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 3.79
A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol (2006) 3.40
QMEAN server for protein model quality estimation. Nucleic Acids Res (2009) 3.39
Calculation of absolute protein-ligand binding free energy from computer simulations. Proc Natl Acad Sci U S A (2005) 3.21
Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. Biophys J (2006) 2.88
Computations of standard binding free energies with molecular dynamics simulations. J Phys Chem B (2009) 2.80
The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure (2005) 2.78
A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A (2008) 2.18
Finding transition pathways using the string method with swarms of trajectories. J Phys Chem B (2008) 2.17
How does a drug molecule find its target binding site? J Am Chem Soc (2011) 2.13
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 1.98
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res (2006) 1.98
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure (2007) 1.87
Calculation of Standard Binding Free Energies: Aromatic Molecules in the T4 Lysozyme L99A Mutant. J Chem Theory Comput (2006) 1.77
Computation of binding free energy with molecular dynamics and grand canonical Monte Carlo simulations. J Chem Phys (2008) 1.66
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem (2004) 1.55
Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem Biol (2008) 1.41
Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem (2008) 1.38
Free Energy Perturbation Hamiltonian Replica-Exchange Molecular Dynamics (FEP/H-REMD) for Absolute Ligand Binding Free Energy Calculations. J Chem Theory Comput (2010) 1.35
Computation of Absolute Hydration and Binding Free Energy with Free Energy Perturbation Distributed Replica-Exchange Molecular Dynamics (FEP/REMD). J Chem Theory Comput (2009) 1.30
Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins (2008) 1.23
The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J Am Chem Soc (2012) 1.20
Resistance to imatinib: mutations and beyond. Semin Hematol (2010) 1.08
Absolute binding free energy calculations of sparsomycin analogs to the bacterial ribosome. J Phys Chem B (2010) 1.03
Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem (2010) 1.01
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. Biochemistry (2010) 1.00
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer (2008) 0.99
Acid-base profiling of imatinib (gleevec) and its fragments. J Med Chem (2005) 0.89
Binding free energy calculation with QM/MM hybrid methods for Abl-Kinase inhibitor. J Biol Phys (2010) 0.87
Calculation of the standard binding free energy of sparsomycin to the ribosomal peptidyl-transferase P-site using molecular dynamics simulations with restraining potentials. J Mol Recognit (2010) 0.85
A molecular mechanics model for imatinib and imatinib:kinase binding. J Comput Chem (2010) 0.82
Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics. Recent Pat Anticancer Drug Discov (2009) 0.81
High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05
Molecular determinants of gating at the potassium-channel selectivity filter. Nat Struct Mol Biol (2006) 4.64
Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands. Nature (2004) 4.37
PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol (2002) 3.51
Closing in on the resting state of the Shaker K(+) channel. Neuron (2007) 3.49
Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res (2009) 3.44
Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am (2003) 3.36
Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36
Calculation of absolute protein-ligand binding free energy from computer simulations. Proc Natl Acad Sci U S A (2005) 3.21
Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol (2012) 3.19
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest (2009) 3.17
Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell (2008) 3.15
Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell (2005) 3.04
Gating charge displacement in voltage-gated ion channels involves limited transmembrane movement. Nature (2005) 2.98
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. Biophys J (2006) 2.88
Two atomic constraints unambiguously position the S4 segment relative to S1 and S2 segments in the closed state of Shaker K channel. Proc Natl Acad Sci U S A (2007) 2.85
Computations of standard binding free energies with molecular dynamics simulations. J Phys Chem B (2009) 2.80
Importance of hydration and dynamics on the selectivity of the KcsA and NaK channels. J Gen Physiol (2007) 2.79
Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol (2010) 2.68
Energetics of ion conduction through the gramicidin channel. Proc Natl Acad Sci U S A (2003) 2.67
Structural basis for the coupling between activation and inactivation gates in K(+) channels. Nature (2010) 2.63
Ion permeation and selectivity of OmpF porin: a theoretical study based on molecular dynamics, Brownian dynamics, and continuum electrodiffusion theory. J Mol Biol (2002) 2.61
Molecular driving forces determining potassium channel slow inactivation. Nat Struct Mol Biol (2007) 2.56
Retracted CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med (2013) 2.51
A gate in the selectivity filter of potassium channels. Structure (2005) 2.50
The free energy landscapes governing conformational changes in a glutamate receptor ligand-binding domain. Structure (2007) 2.45
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol (2006) 2.40
Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity (2013) 2.39
Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem (2004) 2.35
Cell cycle-dependent translocation of PRC1 on the spindle by Kif4 is essential for midzone formation and cytokinesis. Proc Natl Acad Sci U S A (2004) 2.29
Ion selectivity in potassium channels. Biophys Chem (2006) 2.28
Control of ion selectivity in LeuT: two Na+ binding sites with two different mechanisms. J Mol Biol (2008) 2.27
A microscopic view of ion conduction through the K+ channel. Proc Natl Acad Sci U S A (2003) 2.24
Ions and counterions in a biological channel: a molecular dynamics simulation of OmpF porin from Escherichia coli in an explicit membrane with 1 M KCl aqueous salt solution. J Mol Biol (2002) 2.23
Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells. Blood (2007) 2.18
Finding transition pathways using the string method with swarms of trajectories. J Phys Chem B (2008) 2.17
CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol (2006) 2.15
Absolute hydration free energy scale for alkali and halide ions established from simulations with a polarizable force field. J Phys Chem B (2006) 2.15
The hidden energetics of ligand binding and activation in a glutamate receptor. Nat Struct Mol Biol (2011) 2.10
Dynamics of the Kv1.2 voltage-gated K+ channel in a membrane environment. Biophys J (2007) 2.10
Efficacy of platelet-rich plasma combined with allograft bone in the management of displaced intra-articular calcaneal fractures: a prospective cohort study. J Orthop Res (2012) 2.04
Modeling the structure of agitoxin in complex with the Shaker K+ channel: a computational approach based on experimental distance restraints extracted from thermodynamic mutant cycles. Biophys J (2002) 1.98
MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res (2010) 1.94
Molecular mechanism of H+ conduction in the single-file water chain of the gramicidin channel. Biophys J (2002) 1.94
Ion permeation through the alpha-hemolysin channel: theoretical studies based on Brownian dynamics and Poisson-Nernst-Plank electrodiffusion theory. Biophys J (2004) 1.91
The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron (2002) 1.91
A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev (2009) 1.87
Calculation of the gating charge for the Kv1.2 voltage-activated potassium channel. Biophys J (2010) 1.87
Polarizable empirical force field for the primary and secondary alcohol series based on the classical Drude model. J Chem Theory Comput (2007) 1.86
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 1.84
Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One (2008) 1.83
An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis (2005) 1.82
Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol (2010) 1.80
Multidomain assembled states of Hck tyrosine kinase in solution. Proc Natl Acad Sci U S A (2010) 1.79
Polarizable empirical force field for aromatic compounds based on the classical drude oscillator. J Phys Chem B (2007) 1.77
Spatiotemporal control of spindle midzone formation by PRC1 in human cells. Proc Natl Acad Sci U S A (2006) 1.73
An emerging consensus on voltage-dependent gating from computational modeling and molecular dynamics simulations. J Gen Physiol (2012) 1.72
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets (2004) 1.72
A cryptographic approach to securely share and query genomic sequences. IEEE Trans Inf Technol Biomed (2008) 1.71
Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem (2004) 1.71
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A (2009) 1.70
Force field bias in protein folding simulations. Biophys J (2009) 1.67
Computation of binding free energy with molecular dynamics and grand canonical Monte Carlo simulations. J Chem Phys (2008) 1.66
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet (2012) 1.64
High-cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst (2012) 1.63
A rapid coarse residue-based computational method for x-ray solution scattering characterization of protein folds and multiple conformational states of large protein complexes. Biophys J (2009) 1.63
PBEQ-Solver for online visualization of electrostatic potential of biomolecules. Nucleic Acids Res (2008) 1.61
Structural basis of two-stage voltage-dependent activation in K+ channels. Proc Natl Acad Sci U S A (2003) 1.61
Electrostatics of ion stabilization in a ClC chloride channel homologue from Escherichia coli. J Mol Biol (2004) 1.61
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A (2005) 1.60
Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol (2008) 1.59
Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res (2010) 1.58
Decreased expression of CD36 in circumvallate taste buds of high-fat diet induced obese rats. Acta Histochem (2010) 1.58
Understanding the dielectric properties of liquid amides from a polarizable force field. J Phys Chem B (2008) 1.57
BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med (2008) 1.54
Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest (2008) 1.54
The N-terminal end of the catalytic domain of SRC kinase Hck is a conformational switch implicated in long-range allosteric regulation. Structure (2005) 1.53
Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg (2012) 1.53
Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem (2003) 1.52
Molecular basis of proton blockage in aquaporins. Structure (2004) 1.51
Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem (2008) 1.48
Electrostatics of the intracellular vestibule of K+ channels. J Mol Biol (2005) 1.48
Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis (2005) 1.47
Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev (2009) 1.47
SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res (2009) 1.45
Free energy landscape of A-DNA to B-DNA conversion in aqueous solution. J Am Chem Soc (2005) 1.44
Src kinase conformational activation: thermodynamics, pathways, and mechanisms. PLoS Comput Biol (2008) 1.43
Structural determinants of proton blockage in aquaporins. J Mol Biol (2004) 1.43
Simulated x-ray scattering of protein solutions using explicit-solvent models. J Chem Phys (2009) 1.43
DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther (2009) 1.42
Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med (2008) 1.42
The ionization state and the conformation of Glu-71 in the KcsA K(+) channel. Biophys J (2002) 1.41
High-performance scalable molecular dynamics simulations of a polarizable force field based on classical Drude oscillators in NAMD. J Phys Chem Lett (2011) 1.41
TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem (2010) 1.40
Electroconvulsive therapy in China: clinical practice and research on efficacy. J ECT (2012) 1.40
Molecular dynamics study of hydration in ethanol-water mixtures using a polarizable force field. J Phys Chem B (2005) 1.39
Simulating Monovalent and Divalent Ions in Aqueous Solution Using a Drude Polarizable Force Field. J Chem Theory Comput (2010) 1.39
Atomistic view of the conformational activation of Src kinase using the string method with swarms-of-trajectories. Biophys J (2009) 1.37
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer (2002) 1.37